. GLS and GLS2 are inversely associated in multiple models of EMT-induced cell lines. (A) Representative immunofluorescent images of HMLER-vector (V), HMLER-SNAIL (S), and HMLER-FOXC2 (F) cells stained with human GLS2 antibody (green) co-stained with Dapi (blue). Scale bar: 20 S2 of S5 µm. (B) GLS2 mRNA expression in MCF7 (n = 3), SUM159 (n = 3), MDA231 (n = 3), and MDA468 (n = 3) cells. (C) RT-PCR of GLS mRNA in MCF7, SUM159, and MDA-MB231 (n = 3). (D) GLS2 mRNA levels in MCF10A cells treated with 5 ng/mL of TGFβ for 12, 24, 48, 96, and 144 hours (n = 3) . (E) RT-PCR of GLS mRNA in MCF10A cells treated with 5 ng/mL of TGFβ for 0, 12, 24, 48, 96, and 144 hours (n = 3) . (F) Copy number change of GLS2 in breast cancer patient samples. Deletion in one copy (-1) of GLS2 gene is observed in 143 patients in the TCGA Breast cancer cohort. (G) Amplifications (red, copy number gain, +1 and amplification, +2) and deletions (blue, copy number loss, −1 and deletion, −2) of GLS and GLS2 by PAM50 subtype.The data are reported as means +/− SD; NS indicates p > 0.05, * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
